New Analysis Shows Use of EXPAREL Associated with Improved Clinical and Economic Outcomes Following Hip Replacement Surgery

World News: . []

PARSIPPANY, N.J., June 12, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension) following total hip arthroplasty (THA). The findings show that patients receiving EXPAREL had a significant reduction in opioid use, hospital length of stay (LOS), and total hospitalization costs compared to THA patients who did not receive the product. The results were published in

This retrospective analysis utilized data from the Premier Healthcare Database from January 2011 through April 2017 for the ten hospitals in the United States with the highest number of THA procedures using EXPAREL. Patients undergoing THA who received EXPAREL were matched in a one-to-one ratio to a control group of patients whose pain management strategy did not include the product. The study population included a total of 12,589 patients, with 7,232 Medicare patients and 5,357 commercial insurance patients.

Results showed that patients undergoing THA who received EXPAREL compared to those who did not demonstrated a significant:

“When pain is not managed properly following total hip arthroplasty surgery, patients may experience an increase in hospital length of stay, opioid consumption and an overall delayed recovery,” said Carl Asche, PhD, Research Professor 1 and Director of the Center for Outcomes Research at the University of Illinois College of Medicine at Peoria and lead author on the study publication. “This can result in an increase in hospitalization costs as well. Our data illustrates that successful use of EXPAREL can offer improved patient outcomes, as well as economic benefits for hospitals, during THA procedures.”

Results of this study are consistent with findings from several retrospective studies and randomized controlled trials on the use of EXPAREL for total joint replacement procedures, including from Dr. Asche, published last year in that found a decrease in opioid consumption, hospital LOS and hospitalization costs for patients receiving EXPAREL following total knee arthroplasty TKA.

Between 2013 and 2015, an estimated one in five American adults reported a diagnosis of arthritis, the most common being osteoarthritis, which often requires THA. This procedure is growing steadily, with research estimating 572,000 annual THAs will be conducted in the U.S. by 2030.

Company Contact:
Pacira BioSciences, Inc.
Susan Mesco, (973) 451-4030
Susan.Mesco@pacira.com

Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
aschneider@coynepr.com

More news and information about Pacira BioSciences

Published By:

Globe Newswire: 12:30 GMT Wednesday 12th June 2019

Published: .

Search for other references to "analysis" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us